Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy-Reference-Cited by-同舟云学术

Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy

Published:2022-05 Issue: Volume:17 Page:100163
ISSN:2666-6022
Container-title:American Heart Journal Plus: Cardiology Research and Practice
language:en
Short-container-title:American Heart Journal Plus: Cardiology Research and Practice

Author:

Van Dril Elizabeth,Allison Margaret,Schumacher Christie

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Estimates of Diabetes and Its Burden in the United States,2020

2. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data;Gregg;Lancet,2018

3. Standards of Medical Care in Diabetes - 2022;Diabetes Care,2022

4. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary;Garber;Endocr. Pract.,2020

5. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines;Arnett;Circulation,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insulin for people with type 2 diabetes mellitus;BMJ;2024-07-17

2. GLP-1 RAs and SGLT2-Is to Lower Glucose and Reduce the Risk of Cardiovascular and Diabetic Kidney Disease;The Journal of the American Board of Family Medicine;2024-05

3. Impact of Initiating a GLP1 Agonist and/or SGLT2 Inhibitor Therapy on De-Escalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team;Journal of Primary Care & Community Health;2024-01

4. Semaglutide and the future of obesity care in the UK;The Lancet;2023-06

5. Clinical efficacy of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis;Cellular and Molecular Biology;2023-04-30